Pro-Dex, Inc. (NASDAQ:PDEX) Director Raymond E. Cabillot Sells 836 Shares

Pro-Dex, Inc. (NASDAQ:PDEX - Get Free Report) Director Raymond E. Cabillot sold 836 shares of the business's stock in a transaction dated Monday, March 31st. The shares were sold at an average price of $50.00, for a total value of $41,800.00. Following the completion of the sale, the director now directly owns 278,109 shares of the company's stock, valued at $13,905,450. The trade was a 0.30 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Pro-Dex Stock Down 7.4 %

Shares of NASDAQ:PDEX traded down $4.07 during mid-day trading on Thursday, hitting $51.12. 43,653 shares of the company traded hands, compared to its average volume of 22,768. The stock has a 50-day moving average price of $40.72 and a two-hundred day moving average price of $40.53. Pro-Dex, Inc. has a 12-month low of $16.84 and a 12-month high of $59.60. The stock has a market cap of $166.70 million, a P/E ratio of 25.43 and a beta of 0.40. The company has a current ratio of 2.58, a quick ratio of 1.44 and a debt-to-equity ratio of 0.33.

Pro-Dex (NASDAQ:PDEX - Get Free Report) last posted its quarterly earnings data on Thursday, January 30th. The medical instruments supplier reported $0.61 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.38 by $0.23. Pro-Dex had a net margin of 11.06% and a return on equity of 21.68%. On average, equities research analysts forecast that Pro-Dex, Inc. will post 2 earnings per share for the current year.

Remove Ads

Wall Street Analyst Weigh In

Separately, StockNews.com lowered shares of Pro-Dex from a "buy" rating to a "hold" rating in a report on Wednesday, March 12th.

Hedge Funds Weigh In On Pro-Dex

Several institutional investors have recently modified their holdings of the business. FMR LLC boosted its position in Pro-Dex by 34.9% in the third quarter. FMR LLC now owns 3,973 shares of the medical instruments supplier's stock worth $119,000 after purchasing an additional 1,028 shares during the last quarter. Bank of New York Mellon Corp purchased a new position in shares of Pro-Dex in the 4th quarter worth about $202,000. Trexquant Investment LP bought a new position in Pro-Dex during the fourth quarter valued at about $252,000. Integrated Quantitative Investments LLC purchased a new stake in Pro-Dex during the fourth quarter worth about $254,000. Finally, Arrowstreet Capital Limited Partnership purchased a new stake in Pro-Dex during the fourth quarter worth about $255,000. 15.28% of the stock is owned by institutional investors.

About Pro-Dex

Pro-Dex, Inc designs, develops, manufactures, and sells powered surgical instruments for medical device original equipment manufacturers worldwide. The company offers autoclavable, battery-powered and electric, and multi-function surgical drivers and shavers that are primarily used in the orthopedic, thoracic, and craniomaxillofacial markets.